English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Metformin and glibenclamide may have beneficial effects on the levels of trace elements in diabetic patients. The aim of the current study was to assess the effects of metformin and glibenclamide on the concentrations of copper ( Cu ), zinc ( Zn ) and magnesium ( Mg ) in patients with type 2 diabetes mellitus. The metformin-treated patients showed significantly lower serum  Cu  levels compared with the untreated and glibenclamide groups. In addition, treatment with metformin was associated with a significant increase in serum concentrations of  Zn  compared to the newly diagnosed patients, whereas it did not show a noticeable alteration in the serum level of  Mg . In contrast, the glibenclamide treated group revealed significantly higher  Zn  and  Mg  levels compared with the newly diagnosed group, while the serum level of  Cu  was not significantly modified. In conclusion, treatment with metformin led to a reduction in serum  Cu  and an increase in serum  Zn  concentrations, whereas glibenclamide treatment displayed enhancement in serum  Zn  and  Mg  levels.

Assessment of the effects of metformin and glibenclamide on the concentration of selected trace elements in type 2 diabetic patients